CRISPR Therapeutics (NasdaqGM:CRSP) reports significant progress in the commercial rollout of Casgevy, its approved gene editing therapy for sickle cell disease. Patient initiations for Casgevy have ...
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.
UC San Diego researchers have created a new system that reveals specific categories of potentially risky mutations resulting from CRISPR edits. This high magnification image reveals CRISPR-based DNA ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
10d
Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Mixed Trading And Discounted P/B Ratio
CRISPR Therapeutics overview after recent trading moves CRISPR Therapeutics (CRSP) has seen mixed trading recently, with the ...
A new technique brings CRISPR-mediated gene editing together with spatial transcriptomics and imaging to study the intercellular effects of gene perturbation.
Morning Overview on MSN
Some brain cells resist dementia and scientists finally cracked the code
Researchers have identified a specific protein complex inside neurons that tags toxic tau fragments for destruction, offering the clearest explanation yet for why certain brain cells survive while ...
CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results